

Special Issue

A Modern Take on Replicating Viral Vaccines

Message from the Guest Editors

Arguably the greatest accomplishments in curtailing viral diseases have been made possible by live-attenuated vaccines. Modern molecular techniques and research into virology, immunology, and pathogenesis enable the design of safe and potent novel candidates, yet the live-attenuated approach seems to have gone out of fashion. Is there still a place for attenuated vaccines, or have other approaches, like mRNA, made them obsolete? This Special Issue welcomes articles that probe various topics around live-attenuated vaccine candidates against important viral diseases. We welcome rational attenuation strategies, characterization of natural strain variation, efficacy and safety results in animal models and the clinic, studies of genetic stability, immunological correlates of protection, and comparative pathology. Additionally, we are interested in reports on reversion, shedding, or other topics with safety implications. Let us make this Special Issue a thought-provoking forum on the possibilities and special considerations of this approach!

Guest Editors

Dr. Markus Kainulainen

Viral Special Pathogens Branch, Centers for Disease Control and Prevention (CDC), Atlanta, GA 30329, USA

Dr. Anthony Griffiths

National Infectious Diseases Laboratories, Boston University, Boston, MA, USA

Deadline for manuscript submissions

closed (31 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/90477

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).